ADAM17 and lung carcinoma: In a lung cancer patient cohort, both high expression of ADAM17 and PSEN2 were correlated with better first progression survival of patients who underwent systemic therapy while in a breast cancer patient cohort, ADAM17 and PSEN2 expression led to a much narrower gap in relapse-free survival (RFS) of patients who underwent systemic therapy compared to the significantly wide gap in overall survival of patients under the systemically untreated cohort (Supplementary Fig. S10a,b).